Elevance Health Inc

Latest Report Overview

Elevance Health Inc $ELV reported Q1 2026 revenue of $50.181 billion, reflecting a 2.6% increase compared to the same period in the prior year. Net income for the quarter stood at $1.76 billion, with operating margins reaching 4.2% and earnings per share holding steady. The company maintained a robust cash position of $9.66 billion against $31.84 billion in total debt, supported by a healthy operating cash flow of $4.33 billion during the period. Business performance in the quarter was underpinned by sustained demand across both the Health Benefits and Carelon segments, despite continued pressure from medical cost trends. The company noted that membership attrition in Medicaid, linked to ongoing eligibility redetermination processes, was partially offset by growth in Medicare Advantage and individual market enrollments. Efforts to streamline operating expenses and integrate Carelon service capabilities continue to be a central theme of quarterly operational performance. Management continues to prioritize long-term value creation through balanced capital allocation, including a commitment to share repurchases and strategic investments in Carelon's clinical and digital health services. The outlook remains focused on navigating the evolving regulatory environment, including shifts in Medicare Advantage funding and CMS Star Rating methodologies, as the company seeks to maintain its competitive stance in the government-sponsored health landscape.

Key Takeaways for Elevance Health Inc

• Q1 2026 revenue grew 2.6% YoY to $50.18 billion, reflecting moderate top-line expansion in a challenging regulatory environment.
• Medicare Advantage membership growth continues to be a strategic offset to ongoing Medicaid membership attrition, which is pressured by state eligibility redeterminations.
• The Carelon segment remains a critical focal point for management, driving service revenue growth and serving as a differentiator to improve medical loss ratio (MLR) management.
• The company's capital allocation strategy remains focused on shareholder returns, with $413M in common stock repurchased in Q4 2025 and continued commitment to dividends, despite heavy investment needs.
• Regulatory headwinds, particularly Medicare Advantage funding rates and CMS Star Rating adjustments, remain the most significant material risk to near-term earnings guidance.
• Management is actively managing the transition away from offering Medicare Part D plans in 2026, a move expected to simplify the portfolio and reduce complexity in the Medicare business.
• Cybersecurity and data integrity remain high-priority operational concerns, with the company maintaining extensive investments in its information systems and resilience programs.